Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

676 recalls · Class II, newest first

Class II · Moderate risk

Kingskin

cGMP deviations

Terminated cGMP deviation Pharmadel, LLC NDC 55758-409-15 D-0381-2025
Class II · Moderate risk

ChlorproMAZINE Hydrochloride Tablets

CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit

Ongoing Nitrosamine impurity The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7129-61 D-0366-2025
Class II · Moderate risk

clomiPRAMINE hydrochloride Capsules USP

Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during 18-month long term stability study.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-492-01 D-0377-2025
Class II · Moderate risk

Testosterone Cypionate Injection

cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.

Ongoing cGMP deviation Eugia US LLC NDC 55150-277-01 D-0363-2025
Class II · Moderate risk

Wegovy (semaglutide)

Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released.

Ongoing Temperature excursion Cardinal Health Inc. NDC 0169-4524-14 D-0393-2025

Recalls by year